OOIR: Observatory of International Research

Papers

(The H4-Index of European Journal of Medicinal Chemistry is 62. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
Oxidative stress mitigation by antioxidants - An overview on their chemistry and influences on health status	332
Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: A minireview	276
Current trends in computer aided drug design and a highlight of drugs discovered via computational techniques: A review	251
β-lactam antibiotics: An overview from a medicinal chemistry perspective	239
Alzheimer’s disease and its treatment by different approaches: A review	209
An insight on medicinal attributes of 1,2,4-triazoles	166
Recent developments of gallic acid derivatives and their hybrids in medicinal chemistry: A review	163
RNA-dependent RNA polymerase (RdRp) inhibitors: The current landscape and repurposing for the COVID-19 pandemic	138
Application of sulfoximines in medicinal chemistry from 2013 to 2020	133
A comprehensive review of monoamine oxidase inhibitors as Anti-Alzheimer’s disease agents: A review	131
Bioactive pyrrole-based compounds with target selectivity	130
hERG toxicity assessment: Useful guidelines for drug design	126
Antibacterial activities with the structure-activity relationship of coumarin derivatives	119
The development of Coronavirus 3C-Like protease (3CLpro) inhibitors from 2010 to 2020	118
Research progress of mTOR inhibitors	117
Design and discovery of boronic acid drugs	116
Small molecule selenium-containing compounds: Recent development and therapeutic applications	114
Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges	112
Anticancer property of ginsenoside Rh2 from ginseng	106
Chalcone hybrids as privileged scaffolds in antimalarial drug discovery: A key review	100
The importance of indole and azaindole scaffold in the development of antitumor agents	97
Indole-based derivatives as potential antibacterial activity against methicillin-resistance Staphylococcus aureus (MRSA)	96
Pyrazole-based analogs as potential antibacterial agents against methicillin-resistance staphylococcus aureus (MRSA) and its SAR elucidation	95
In vitro and in vivo anticancer activity of tridentate thiosemicarbazone copper complexes: Unravelling an unexplored pharmacological target	86
Synthetic and medicinal perspective of quinolines as antiviral agents	86

Toll-like receptor 4 (TLR4) inhibitors: Current research and prospective	82
Treatment for liver cancer: From sorafenib to natural products	82
Sulfonamide derivatives as potential anti-cancer agents and their SARs elucidation	82
Plant isoquinoline alkaloids: Advances in the chemistry and biology of berberine	82
A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir	78
A review: Pharmacological aspects of metal based 1,2,4-triazole derived Schiff bases	77
Recent advance on PTP1B inhibitors and their biomedical applications	77
Recent advances in the medicinal chemistry of carbonic anhydrase inhibitors	77
Current development of CBP/p300 inhibitors in the last decade	76
Recent advancements in the development of bioactive pyrazoline derivatives	73
Discovery of natural anti-inflammatory alkaloids: Potential leads for the drug discovery for the treatment of inflammation	73
1,2,3-Triazole-containing hybrids with potential antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA)	73
A medicinal chemistry perspective of drug repositioning: Recent advances and challenges in drug discovery	72
Therapeutic strategies to overcome cisplatin resistance in ovarian cancer	72
The application of isatin-based multicomponent-reactions in the quest for new bioactive and druglike molecules	72
Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes	72
PROTACs to address the challenges facing small molecule inhibitors	70
Current scenario of indole derivatives with potential anti-drug-resistant cancer activity	69
A review: Biologically active 3,4-heterocycle-fused coumarins	69
Recent accomplishments on the synthetic/biological facets of pharmacologically active 1H-1,2,3-triazoles	68
FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application	68
Cancer multidrug-resistance reversal by ABCB1 inhibition: A recent update	67
Quercetin derivatives: Drug design, development, and biological activities, a review	67
Chemotherapy and chemo-resistance in nasopharyngeal carcinoma	66
Developments of CRBN-based PROTACs as potential therapeutic agents	66
Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment	66
Discovery of novel resorcinol diphenyl ether-based PROTAC-like molecules as dual inhibitors and degraders of PD-L1	66
Camptothecin's journey from discovery to WHO Essential Medicine: Fifty years of promise	66
A review on the structure and pharmacological activity of phenylethanoid glycosides	65
Azithromycin: The First Broad-spectrum Therapeutic	65
Novel quinazoline-based EGFR kinase inhibitors: A review focussing on SAR and molecular docking studies (2015-2019)	65
Recent advancements in the development of heterocyclic anti-inflammatory agents	64
Antimicrobial drugs bearing guanidine moieties: A review	64
Penicillin binding protein 2a: An overview and a medicinal chemistry perspective	63
Recent advances in DNA gyrase-targeted antimicrobial agents	63
Contemporary approaches and future perspectives of antibacterial photodynamic therapy (aPDT) against methicillin-resistant Staphylococcus aureus (MRSA): A systematic review	63
Pt(II) and Au(III) complexes containing Schiff-base ligands: A promising source for antitumor treatment	62
Exploration of carbamide derived pyrimidine-thioindole conjugates as potential VEGFR-2 inhibitors with anti-angiogenesis effect	62
Resveratrol – A comprehensive review of recent advances in anticancer drug design and development	62